Publication not explained

This publication has not yet been explained in plain language by the author(s). However, you can still read the publication.

If you are one of the authors, claim this publication so you can create a plain language summary to help more people find, understand and use it.

Featured Image

Read the Original

This page is a summary of: Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03, Journal of Clinical Oncology, February 2016, American Society of Clinical Oncology (ASCO),
DOI: 10.1200/jco.2015.61.3968.
You can read the full text:

Read

Contributors

The following have contributed to this page